Recombinant MYOD1 antibody (AA 1-100)
Quick Overview for Recombinant MYOD1 antibody (AA 1-100) (ABIN7867874)
Target
See all MYOD1 AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 1-100
-
Purpose
- Recombinant Myoblast determination protein 1 Antibody / MyoD1
-
Purification
- Protein A/G affinity
-
Immunogen
- A recombinant fragment (within amino acids 1-100) of human MyoD1 protein was used as the immunogen for the recombinant Myoblast determination protein 1 antibody.
-
Isotype
- IgG, kappa
-
-
-
-
Application Notes
- Optimal dilution of the recombinant Myoblast determination protein 1 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Aliquot the recombinant Myoblast determination protein 1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- MYOD1 (Myogenic Differentiation 1 (MYOD1))
-
Alternative Name
- Myoblast determination protein 1
-
Background
- MyoD1, one of the MyoD family of myogenic helix-loop-helix transcription factors, combined with myogenin, plays a role in coordinating the myogenic differentiation pathway from the determination of mesodermal precursors into myoblasts, the differentiation of myoblasts into myotubes, and finally the maturation of myotubes into skeletal myofibers. Normal mature skeletal muscle does not express MyoD1 protein. MyoD1 is expressed in myoblasts before differentiation while myogenin has post-differentiation functions. Anti-MyoD1 immunostaining identifies cells committed to myogenesis in their earliest phase, thus, it is a better biomarker for less differentiated Rhabdomyosarcomas (RMS). RMS are the most frequent malignant soft tissue neoplasms of childhood. While better differentiated RMS have cross-striations or rhabdomyoblasts that allow for a confident morphologic diagnosis, less differentiated RMS resemble other small blue round-cell tumors. Studies suggest, anti-MyoD1 may be used together with anti-Myogenin and anti-Desmin as a panel of markers since any RMS is virtually never negative for all three markers simultaneously.
-
UniProt
- P15172
-
Pathways
- Regulation of Muscle Cell Differentiation, Skeletal Muscle Fiber Development
Target
-